[Treatment of myotonic dystrophy].
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D000328:Adult; D002707:Chlordiazepoxide / Q000627:therapeutic use; D002720:Chlormezanone / Q000627:therapeutic use; D003975:Diazepam / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007475:Ion Exchange Resins / Q000627:therapeutic use; D008297:Male; D008615:Mephenesin / Q000627:therapeutic use; D008721:Methocarbamol / Q000627:therapeutic use; D009222:Myotonia / Q000188:drug therapy* / Q000503:physiopathology; D010672:Phenytoin / Q000627:therapeutic use; D011342:Procainamide / Q000627:therapeutic use; D011803:Quinine / Q000627:therapeutic use; D013963:Thyroid Hormones / Q000627:therapeutic use; D015049:Zoxazolamine / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D007475:Ion Exchange Resins; D013963:Thyroid Hormones; D008721:Methocarbamol; D010672:Phenytoin; D002707:Chlordiazepoxide; D008615:Mephenesin; D000324:Adrenocorticotropic Hormone; D015049:Zoxazolamine; D011803:Quinine; D002720:Chlormezanone; D011342:Procainamide; D003975:Diazepam